Anti-ICAM1 (Enlimomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-ICAM1 (Enlimomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (ADC-W-1213)
This ADC product is comprised of an anti-ICAM1 Fab' fragment conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
Name
ICAM1
Alternative Names
ICAM1; intercellular adhesion molecule 1; BB2; CD54; human rhinovirus receptor; ICAM-1; cell surface glycoprotein P3.58; major group rhinovirus receptor; intercellular adhesion molecule 1 (CD54), human rhinovirus receptor; P3.58;
This gene encodes a cell surface glycoprotein which is typically expressed on endothelial cells and cells of the immune system. It binds to integrins of type CD11a / CD18, or CD11b / CD18 and is also exploited by Rhinovirus as a receptor.
ADC Antibody
Overview
Human Anti-ICAM1 IgG2-Fab’ fragment , Enlimomab
Generic name
Enlimomab
Host animal
Mouse
ADC Linker
Name
MC-Vc-PAB-DMEA-(PEG2)
Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
duocarmycin SA
Description
Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.